Bellerophon to Present at Two September Investor Conferences

WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that Fabian Tenenbaum, Chief Executive Officer, will present at two investor conferences in September: H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Fitzgerald Virtual Global Healthcare Conference.

H.C. Wainwright 22nd Annual Global Investment Conference

Date:	Monday, September 14, 2020
Time:	5:00 PM ET

Cantor Fitzgerald Virtual Global Healthcare Conference

Date:	Thursday, September 17, 2020
Time:	2:40 PM ET

A live audio webcast and replay of the presentations will be available in the Investors section on the Company’s website at www.bellerophon.com.

About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts
At W2O Group:	At LifeSci Advisors:
Julie Normart	Brian Ritchie
(559) 974-3245	(212) 915-2578
[email protected]	[email protected]

 

Source: Bellerophon Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Prairie Provident Resources Announces Second Quarter 2026 Results
• Crypto News Confirms Samsung Building Stablecoin Payments and Smart Wallets Are Rushing Into Pepeto
• Northland Power Reports Second Quarter 2026 Results and Construction Progress Updates